Previously recommended treatment regimens for drug-resistant tuberculosis (DR-TB) used by most countries had a high pill burden, long treatment duration (of up to two years), painful daily injections (for up to eight months), severe side effects (due to toxic drugs) and poor treatment outcomes. These suboptimal regimens achieved treatment success rates of only 55% for people with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) and 34% for people with extensively drug-resistant TB.
The World Health Organization (WHO) issued new MDR/RR-TB treatment guidelines in March 2019. This technical brief provides a summary of the treatment regimens now recommended by WHO, which represent hope for people with DR-TB and their caregivers because they offer better cure rates and fewer side effects using safer all-oral treatment.
Médecins Sans Frontières (MSF) urges countries to make a timely switch to the...
In the era of declining development assistance for health, transitioning externally funded programs to governments becomes a priority for donors. However, the process requires a careful approach not only to preserve the public health gains that have already been achieved but also to expand on them. In the Eastern Europe and Central Asia region, countries are expected to graduate from support from the Global Fund to Fight AIDS, Tuberculosis and Malaria in or before 2025. We aim to describe transition risks and identify possible means to address them.
Publisher: Journal of the American Medical Association
In 2015, member states of the United Nations adopted the ambitious Sustainable Development Goals (SDGs), which included 17 global goals that targeted economic and social development.1 Goal 3, “to ensure healthy lives and promote well-being for all at all ages,” targets specifically marked progress in universal health coverage; improved access to safe, effective, and affordable medicines; and the end of the HIV, malaria, and tuberculosis epidemics by 2030.
This study aims to analyze different patterns and gaps of care along the care cascade across countries and to develop a model to examine the relationship between performance of tuberculosis programmes in high and low burden countries along the tuberculosis care cascade and tuberculosis disease burden.
GFAN members Friends of the Global Fund Europe and Osservatorio AiDS, together with AIDOS, and the theatre company Bluestocking, launched, last month, for World TB Day a short video highlighting the most common stereotypes on TB in Italy.
The video uses ironic messages to shape the audiences’ understanding of the portrayed clichés and highlight the critical role of the Global Fund in addressing the global reach of TB.
Many of the stereotypes portrayed in the video are common in other countries and they wanted to share a version with English subtitles of their video.
The video was initially launched in Italy on World TB Day. They have produced a similar video on HIV/AIDS which can be found below.
A similar video on Malaria will be released later this month.
are part of a joint information campaign to make the Global Fund better
known in Italy ahead of the next replen...
Publisher: O’Neill Institute for National & Global Health Law
The Global Fund to Fight AIDS, Tuberculosis and Malaria has proven highly effective at fighting the world’s major killers. Strong governance and development institutions, however, are necessary for improving health long-term. While some suggest international aid can strengthen institutions, others worry “dead” aid undermines governance. The Fund is a unique aid institution with mechanisms designed to improve transparency and accountability. We constructed a unique dataset to explore whether Global Fund financing has a significant effect on governance and development.